Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLVSNASDAQ:CRISNASDAQ:MTEMNASDAQ:SABS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLVSClovis Oncology$0.43$0.08▼$3.32$11.60M0.248.88 million shs1.16 million shsCRISCuris$2.45-11.6%$1.94$1.02▼$8.48$25.63M3.6973,740 shs70,277 shsMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.534.91 million shsN/ASABSSAB Biotherapeutics$1.71-6.6%$1.67$1.00▼$5.01$15.88M0.5567,061 shs54,620 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLVSClovis Oncology0.00%0.00%0.00%0.00%0.00%CRISCuris0.00%+3.38%+22.50%-13.73%-72.16%MTEMMolecular Templates0.00%0.00%0.00%0.00%-99.99%SABSSAB Biotherapeutics0.00%-5.52%-11.86%+6.21%-47.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLVSClovis OncologyN/AN/AN/AN/AN/AN/AN/AN/ACRISCuris2.7809 of 5 stars3.53.00.00.03.40.01.3MTEMMolecular TemplatesN/AN/AN/AN/AN/AN/AN/AN/ASABSSAB Biotherapeutics3.7339 of 5 stars3.55.00.00.03.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLVSClovis Oncology 0.00N/AN/AN/ACRISCuris 3.00Buy$17.00593.88% UpsideMTEMMolecular Templates 0.00N/AN/AN/ASABSSAB Biotherapeutics 3.00Buy$13.25674.85% UpsideCurrent Analyst Ratings BreakdownLatest CLVS, CRIS, SABS, and MTEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.005/15/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/14/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/1/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $20.004/1/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/31/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLVSClovis Oncology$148.76M0.00N/AN/A($2.15) per share0.00CRISCuris$11.20M2.29N/AN/A$3.34 per share0.73MTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00SABSSAB Biotherapeutics$2.24M7.09N/AN/A$6.21 per share0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLVSClovis Oncology-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/ACRISCuris-$47.41M-$6.23N/AN/AN/A-443.35%-923.37%-78.35%7/30/2025 (Estimated)MTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/ASABSSAB Biotherapeutics-$42.19M-$3.70N/AN/AN/A-1,450.14%-94.37%-67.26%8/6/2025 (Estimated)Latest CLVS, CRIS, SABS, and MTEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SABSSAB Biotherapeutics-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 million3/31/2025Q4 2024CRISCuris-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million3/28/2025Q4 2024SABSSAB Biotherapeutics-$1.16-$1.23-$0.07-$1.23$0.12 million$0.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLVSClovis OncologyN/AN/AN/AN/AN/ACRISCurisN/AN/AN/AN/AN/AMTEMMolecular TemplatesN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLVSClovis OncologyN/A0.140.12CRISCurisN/A1.221.22MTEMMolecular TemplatesN/A1.561.56SABSSAB Biotherapeutics0.093.693.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLVSClovis Oncology24.53%CRISCuris29.97%MTEMMolecular Templates95.47%SABSSAB Biotherapeutics7.82%Insider OwnershipCompanyInsider OwnershipCLVSClovis Oncology4.40%CRISCuris5.70%MTEMMolecular Templates13.90%SABSSAB Biotherapeutics27.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLVSClovis OncologyN/A144.96 million138.58 millionOptionableCRISCuris6010.46 million7.98 millionNo DataMTEMMolecular Templates2606.58 million5.67 millionNo DataSABSSAB Biotherapeutics1409.29 million6.79 millionNot OptionableCLVS, CRIS, SABS, and MTEM HeadlinesRecent News About These CompaniesSAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | finanznachrichten.deSAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)April 3, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial ResultsApril 2, 2025 | finanznachrichten.deSAB Biotherapeutics price target lowered to $20 from $25 at ChardanApril 2, 2025 | markets.businessinsider.comSAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024March 31, 2025 | markets.businessinsider.comSAB BIO Reports Full Year 2024 Operating and Financial ResultsMarch 31, 2025 | globenewswire.comSAB BIO to Participate in Upcoming Investor ConferencesJanuary 31, 2025 | globenewswire.comStrong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D TreatmentJanuary 29, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 29, 2025 | finanznachrichten.deSAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142January 28, 2025 | globenewswire.comSAB Biotherapeutics (SABS) Gets a Buy from Craig-HallumJanuary 25, 2025 | markets.businessinsider.comSAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D TherapyJanuary 23, 2025 | globenewswire.comHere’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10January 6, 2025 | insidermonkey.comSAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To ConsiderDecember 23, 2024 | finance.yahoo.comSAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)November 9, 2024 | finance.yahoo.comPromising Outlook for SAB Biotherapeutics’ SAB-142 in Type 1 Diabetes Treatment Drives Buy RatingNovember 7, 2024 | markets.businessinsider.comSAB BIO Announces Third Quarter 2024 Financial Results and Provides Company UpdateNovember 6, 2024 | globenewswire.comCraig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)October 15, 2024 | markets.businessinsider.comCraig-Hallum Initiates Coverage of SAB Biotherapeutics (SABS) with Buy RecommendationOctober 10, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLVS, CRIS, SABS, and MTEM Company DescriptionsClovis Oncology NASDAQ:CLVSClovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Curis NASDAQ:CRIS$2.45 -0.32 (-11.55%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$2.57 +0.12 (+4.90%) As of 06/13/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Molecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.SAB Biotherapeutics NASDAQ:SABS$1.71 -0.12 (-6.61%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.71 0.00 (-0.23%) As of 06/13/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
